CAH Rises 8.5% in a Week. Analysts Chase the Stock Higher.

Cardinal Health gained 8.5% over the past week to $271.72, outpacing the median 1.6% weekly move among its closest drug distribution peers, and the analyst community is scrambling to keep pace with a stock that has now risen 16% in the past month.

The options market has quietly turned more defensive into Wednesday's print. The put/call ratio reached 0.80 on Thursday, more than two standard deviations above its 20-day average of 0.70. That is the highest defensive lean in options on CAH in months, sitting well above the 52-week midpoint, even as the underlying has been one of the stronger performers in the sector. The divergence is notable: the stock is being bid up while options traders are adding downside protection at the fastest pace in roughly a year.

Analyst targets have moved sharply in the other direction. Evercore ISI raised its target to $320 on Thursday, the most aggressive call on the Street, up from $270. RBC Capital lifted to $295 the same day. Those two moves alone shifted the consensus mean to $291, against a current price of $271. That 7% implied upside is narrower than it looks, given that MCK fell 1% and COR dropped 1.8% on Friday while CAH added 1.5%, a widening gap that suggests some of the recent outperformance is company-specific rather than sector-driven. Morgan Stanley had already moved to $286 in late October. JPMorgan remains the outlier, holding Neutral, the only major firm not positioned for further gains.

The fundamental debate centers on whether CAH's margin expansion story is durable or priced in. The bull case rests on the pharmaceutical distribution oligopoly, with Cardinal, Cencora, and McKesson controlling more than 90% of the US market, and on the company's growing mix of higher-margin revenue from specialty, biosimilars, and nuclear medicine. The PE multiple has expanded roughly 1.9 points over the past 30 days, reaching 20.2x, reflecting genuine re-rating rather than earnings drift. Bears push back that the core distribution business runs on razor-thin gross margins close to 3.7%, that CVS accounts for roughly 30% of fiscal 2025 sales, and that GLP-1 mix shifts and drug pricing reform could compress economics rather than expand them.

One data point from CAH's own record is worth noting. EDGAR filings show buyback spend of $383 million in the quarter ending October 2025, up 2,453% year-over-year and the largest fourth-quarter buyback figure since 2009. That capital return backdrop sits alongside a 90-day insider net sale of roughly $59.6 million, with CEO Jason Hollar selling approximately $9.1 million worth of shares on August 19. Neither is an unusual pattern for a company with a rising share price, but the contrast between aggressive buybacks and executive selling is a live tension the print will either resolve or extend.

The November 12 report therefore tests a simple question: whether the margin and mix improvement management has described holds through a quarter when both short interest (up 15% over the past month before easing this week) and options positioning have moved in the same cautious direction, while the stock itself has done the opposite.